Hoertkorn Richard Charles’s TriSalus Life Sciences TLSI Stock Holding History

Hoertkorn Richard Charles’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.04K	Hold	668	–	–	﹤0.01%	59
2026 Q1	$2.67K	Hold	668	–	–	﹤0.01%	66
2025 Q4	$4.66K	Hold	668	–	–	﹤0.01%	69
2025 Q3	$3.11K	Hold	668	–	–	﹤0.01%	71
2025 Q2	$3.64K	Hold	668	–	–	﹤0.01%	70
2025 Q1	$3.69K	Hold	668	–	–	﹤0.01%	71
2024 Q4	$3.35K	Hold	668	–	–	﹤0.01%	73
2024 Q3	$3.08K	Hold	668	–	–	﹤0.01%	74
2024 Q2	$3.69K	Hold	668	–	–	﹤0.01%	74
2024 Q1	$6.51K	Hold	668	–	–	﹤0.01%	70
2023 Q4	$5.64K	Buy	+668	New	+$3.44K	﹤0.01%	72

Other funds holding TLSI

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

WPC

White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return

Hoertkorn Richard Charles's TLSI Position: Q2 2026 in Review

Hoertkorn Richard Charles held its TriSalus Life Sciences (TLSI) position steady in Q2 2026 at 668 shares worth $3.04K. The position accounts for ﹤0.01% of the portfolio, ranked #59.

Hoertkorn Richard Charles first reported a position in TLSI in Q4 2023 and has held it in 11 quarters since. The position peaked at $6.51K in Q1 2024. 78 funds tracked by Wall St. Rank hold TLSI as of Q2 2026.

Hoertkorn Richard Charles held 668 shares of TriSalus Life Sciences worth $3.04K as of Q2 2026.
Hoertkorn Richard Charles left its TriSalus Life Sciences share count unchanged in Q2 2026.
TriSalus Life Sciences made up ﹤0.01% of Hoertkorn Richard Charles's portfolio in Q2 2026, its #59 holding.
Hoertkorn Richard Charles first reported a position in TriSalus Life Sciences in Q4 2023 and has held it in 11 quarters since.
Hoertkorn Richard Charles's TriSalus Life Sciences position peaked at $6.51K in Q1 2024.
78 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q2 2026.

Based on Hoertkorn Richard Charles's 13F filing for Q2 2026, filed 23 Jul 2026.